What the FDA labels say about taking them together
Paclitaxel and trastuzumab
Trastuzumab's FDA label of May 29, 2026 names paclitaxel in its warnings and precautions section; the paclitaxel labels PlainMeds reads (4) do not name trastuzumab.
Check it at the source: the paclitaxel FDA label on DailyMed (effective January 21, 2026, Natco Pharma USA LLC); the trastuzumab FDA label on DailyMed (effective May 29, 2026, Genentech, Inc.).
What does the paclitaxel label say about trastuzumab?
Paclitaxel's label (effective January 21, 2026) and its 3 other brand-application labels do not name trastuzumab in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Paclitaxel), Natco Pharma USA LLC, effective January 21, 2026 (SPL set a1eb16b4-285b-4e81-9c4e-1244d4a52af8), via openFDA; the full label on DailyMed
What does the trastuzumab label say about paclitaxel?
Trastuzumab label, warnings and precautionsNSABP B31 & NCCTG N9831 Median follow-up duration for NSABP B31 & NCCTG N9831 combined was 8.3 years in the AC→paclitaxel+Herceptin arm.; AC Anthracycline (doxorubicin) and cyclophosphamide. →Paclitaxel+Herceptin; 3.2% (64/2000) Includes 1 patient with fatal cardiomyopathy and 1 patient with sudden death without documented etiology.; 1.3% (21/1655)
Kanjinti label (Amgen, Inc, June 23, 2026), warnings and precautionsAC Anthracycline (doxorubicin) and cyclophosphamide. → Paclitaxel + Trastuzumab 3.2% (64/2000) Includes 1 patient with fatal cardiomyopathy and 1 patient with sudden death without documented etiology.
Source: FDA drug label (Kanjinti, BLA761073), Amgen, Inc, effective June 23, 2026 (SPL set 9a94f5b2-b84e-4987-8ea1-c4346db5a5fa), via openFDA
Source: FDA drug label (Herzuma, BLA761091), Cephalon, Inc., effective December 22, 2025 (SPL set ae71c003-883a-4cd8-ad50-e8cc9a54e971), via openFDA
Source: FDA drug label (Herceptin), Genentech, Inc., effective May 29, 2026 (SPL set 492dbdb2-077e-4064-bff3-372d6af0a7a2), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Paclitaxel | Trastuzumab | |
|---|---|---|
| Labeled for | Breast cancer, Lung cancer | Breast cancer |
| Boxed warning | Yes | Yes |
| Pharmacy cost (NADAC) | n/a | n/a |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once